List of works - Denis M. Collins

Acquired Resistance to Antibody-Drug Conjugates ⬇️

scientific article published on 20 March 2019

Artificial Neural Networks for Classification in Metabolomic Studies of Whole Cells Using 1H Nuclear Magnetic Resonance ⬇️

scientific article published on September 15, 2010

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

scientific article

Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer

scientific article published on 29 October 2020

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer

scientific article published on 30 July 2018

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer

scientific article published on 27 December 2014

Innovative Technologies Changing Cancer Treatment.

scientific article published on 19 June 2018

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma

scientific article published on 21 July 2015

Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis.

scientific article

Metabolomic studies of human lung carcinoma cell lines using in vitro (1)H NMR of whole cells and cellular extracts.

scientific article

Modulation of P-gp expression by lapatinib.

scientific article published on 6 July 2010

Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference

scientific article published on 07 August 2019

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer

scientific article published on 28 May 2019

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

scientific article published on 2 February 2018

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.

scientific article

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.

scientific article

List of works by Denis M. Collins

Acquired Resistance to Antibody-Drug Conjugates ⬇️

Artificial Neural Networks for Classification in Metabolomic Studies of Whole Cells Using 1H Nuclear Magnetic Resonance ⬇️

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer

HER2-family signalling mechanisms, clinical implications and targeting in breast cancer

Innovative Technologies Changing Cancer Treatment.

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma

Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis.

Metabolomic studies of human lung carcinoma cell lines using in vitro (1)H NMR of whole cells and cellular extracts.

Modulation of P-gp expression by lapatinib.

Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.